



Exploring the role of circulating cell-free DNA in disease diagnosis and therapy

Mohammad Ahmad Ahmad Odah^{1*} 

¹Preparatory Year Deanship, Basic Science Department, Prince Sattam Bin Abdulaziz University, 151 Alkharj 11942, KSA. E-mail: m.odah@psau.edu.sa

Article Info

Volume 1, Issue 2, July 2024

Received : 30 March 2024

Accepted : 14 June 2024

Published: 05 July 2024

doi: [10.62587/AFRJMS.1.2.2024.1-13](https://doi.org/10.62587/AFRJMS.1.2.2024.1-13)

Abstract

Recent advancements in molecular diagnostics have highlighted the potential of circulating cell-free DNA (ccfDNA) as a biomarker in various diseases. This study aims to explore the role of ccfDNA in the early diagnosis, prognosis, and therapeutic monitoring of diseases, with a focus on oncology. We conducted a comprehensive review and analysis of current literature, combined with experimental approaches involving advanced genomic sequencing and bioinformatics techniques. Our research systematically characterizes the molecular composition of ccfDNA, including its origins, size distribution, and methylation patterns, across different disease states. Furthermore, we investigate the dynamics of ccfDNA release and clearance in the bloodstream, elucidating mechanisms that could influence its diagnostic accuracy. In the context of cancer, we analyze the correlation between tumor-derived ccfDNA and disease progression, response to therapy, and overall survival. Our findings indicate that ccfDNA holds promise as a non-invasive biomarker for early disease detection, real-time monitoring of treatment efficacy, and potentially, predicting relapse. This study contributes to the growing field of liquid biopsies and opens new avenues for personalized medicine, emphasizing the need for standardized protocols in ccfDNA analysis to maximize its clinical utility. The implications of our findings extend beyond oncology, suggesting potential applications of ccfDNA in other pathological conditions.

Keywords: Circulating cell-free DNA (ccfDNA), Molecular diagnostics, Liquid biopsies, Cancer biomarkers, Genomic sequencing, Bioinformatics, Personalized medicine

© 2024 Mohammad Ahmad Ahmad Odah. This is an open access article under the CC BY license (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

1. Introduction

The burgeoning field of molecular diagnostics has recently turned its attention to the promising realm of circulating cell-free DNA (ccfDNA), a biomarker with the potential to revolutionize the diagnosis and treatment

* Corresponding author: Preparatory Year Deanship, Basic Science Department, Prince Sattam Bin Abdulaziz University, 151 Alkharj 11942, KSA. E-mail: m.odah@psau.edu.sa

of various diseases, particularly in oncology (Peng *et al.*, 2021). In this comprehensive review, we delve into the intricate role of ccfDNA in early disease detection, prognosis, and therapeutic monitoring. By employing a multidisciplinary approach that blends an extensive literature review with experimental methodologies, this study stands at the forefront of innovative diagnostic techniques.

Our investigation is anchored in advanced genomic sequencing and bioinformatics, tools that are indispensable in decoding the complex molecular signature of ccfDNA. We meticulously characterize the molecular composition of ccfDNA, examining its origins, size distribution, and unique methylation patterns across various disease states. This analysis provides a deeper understanding of the dynamics of ccfDNA release and clearance in the bloodstream, a crucial factor in determining its diagnostic precision.

Focusing on the realm of oncology, our research sheds light on the significant correlation between tumor-derived ccfDNA and key clinical outcomes, including disease progression, treatment response, and overall survival rates. The insights garnered from this study underscore the immense potential of ccfDNA as a non-invasive biomarker that not only aids in early disease detection but also offers real-time monitoring of treatment efficacy, and possibly, in predicting disease relapse.

As we navigate through the intricate landscape of liquid biopsies, our review paves the way for a new era in personalized medicine. It emphasizes the necessity for standardized protocols in ccfDNA analysis to enhance its clinical applicability. The implications of our findings transcend oncology, hinting at the broader applicability of ccfDNA in other pathological conditions, thereby marking a significant milestone in the evolution of molecular diagnostics. This review is not just a culmination of current knowledge but a clarion call for future research in this dynamic field.

2. Scope and objectives of the review

This review aims to provide a comprehensive exploration of the role of ccfDNA in the diagnosis and therapy of diseases, with a special emphasis on oncology. Our objective is to synthesize the current body of knowledge surrounding ccfDNA, from its molecular characteristics and origins to its practical applications in disease prognosis and therapeutic monitoring. We intend to delve into the nuances of ccfDNA analysis methodologies, including genomic sequencing and bioinformatics techniques, and discuss the challenges and future directions in this field.

The review will cover the technological advancements that have propelled the use of ccfDNA, detailing how next-generation sequencing and other genomic analysis tools have enabled the detailed study of ccfDNA. We will explore the origins of ccfDNA, examining how these DNA fragments are released into the bloodstream and how their composition can vary depending on their source, whether it be from normal cellular processes or from pathological conditions like cancer.

Furthermore, we will discuss the current and potential applications of ccfDNA in various medical contexts, emphasizing its role in non-invasive diagnostics, disease monitoring, and personalized treatment strategies. This includes an examination of how ccfDNA can be used to monitor treatment efficacy, detect minimal residual disease, and predict relapse in cancer patients. The review will also explore the challenges faced in ccfDNA analysis, such as issues related to sensitivity and specificity, the need for standardized protocols, and the ethical considerations surrounding the use of genetic information.

By consolidating experimental findings and literature insights, this review endeavors to highlight the potential of ccfDNA as a tool in personalized medicine and its broader implications in various disease contexts beyond oncology. Our aim is to provide a clear and comprehensive understanding of ccfDNA's current applications and future potential, positioning it as a cornerstone in the evolving landscape of molecular diagnostics and personalized healthcare.

3. The emergence of circulating cell-free DNA in molecular diagnostics

The landscape of molecular diagnostics has undergone a significant transformation with the advent of circulating cell-free DNA (ccfDNA), a breakthrough that has opened new avenues in the realm of medical diagnostics and therapeutic monitoring (van Zogchel *et al.*, 2020). ccfDNA, fragments of DNA that circulate freely in the bloodstream, have emerged as a focal point in biomedical research due to their potential in non-

invasive diagnostic procedures, especially in cancer detection and management. This development marks a pivotal shift from traditional biopsy methods, offering a glimpse into real-time disease progression and treatment response through a simple blood sample (Sener *et al.*, 2021).

The rise of ccfDNA has been buoyed by advancements in genomic technologies, enabling the detection and analysis of these DNA fragments with unprecedented precision and sensitivity. Its emergence as a diagnostic tool is particularly transformative in oncology, where early detection and continuous monitoring of cancer are critical for successful treatment outcomes (Telekes and Horváth, 2022). Unlike conventional methods, which often require invasive tissue biopsies and can be limited by tumor accessibility and heterogeneity, ccfDNA provides a holistic view of the tumor genome. This approach not only aids in early cancer detection but also helps in tracking mutations over time, offering invaluable insights into tumor evolution and drug resistance (Tripathi *et al.*, 2022).

Moreover, the utility of ccfDNA extends beyond oncology. It is gaining traction in the diagnosis and management of a range of other conditions, including prenatal genetic testing, organ transplant rejection, cardiovascular diseases, and infectious diseases. This versatility stems from the ability of ccfDNA to reflect various physiological and pathological states of the body, making it an integral component in the broader spectrum of precision medicine (Thakral *et al.*, 2020).

4. Basics of circulating cell-free DNA (ccfDNA)

4.1. Definition and overview

Circulating cell-free DNA (ccfDNA) refers to DNA fragments that are freely circulating in the bloodstream, not contained within cells. These DNA fragments are typically derived from normal cell turnover, as well as from pathological processes like tumor cells in cancer patients. What sets ccfDNA apart is its non-cell-bound nature, making it easily accessible through blood samples. This accessibility is a game-changer in the field of diagnostics, as it allows for the detection and analysis of DNA without the need for invasive procedures (Hosseinalizadeh *et al.*, 2021). The presence and characteristics of ccfDNA, such as its concentration, size distribution, and methylation patterns, can provide invaluable insights into various physiological and pathological states. This makes ccfDNA a powerful tool for non-invasive diagnostic and prognostic purposes. Its analysis can help in the early detection of diseases, monitoring of disease progression, and even in the assessment of treatment efficacy (Carrasco *et al.*, 2022).

The significance of ccfDNA lies in its ability to reflect the genetic and epigenetic landscape of an individual's health status. For instance, the detection of specific mutations in ccfDNA can indicate the presence of certain types of cancer, while changes in the concentration and composition of ccfDNA can signal the effectiveness of a given treatment or the likelihood of disease recurrence. Furthermore, the study of methylation patterns in ccfDNA has opened up new avenues in understanding disease mechanisms, especially in cancer, where abnormal methylation is often a hallmark of malignancy (Ashley *et al.*, 2022).

4.2. Historical perspective and evolution in diagnostics

The discovery and subsequent study of ccfDNA have a rich history, dating back to the late 1940s when it was first observed. Initially, the presence of ccfDNA in human plasma was a curious observation with unclear implications. It wasn't until recent decades, however, that technological advancements in genomic sequencing and molecular diagnostics brought ccfDNA to the forefront of medical research (Gianni *et al.*, 2022). These advancements have allowed for the precise quantification and characterization of ccfDNA, revealing its potential as a biomarker for various diseases (Zhang *et al.*, 2020).

Initially, the focus of ccfDNA research was on its applications in prenatal testing, such as non-invasive prenatal testing (NIPT) for detecting genetic abnormalities in the fetus. This application showcased the potential of ccfDNA to provide critical health information without posing risks to the mother or the fetus, a significant advantage over traditional invasive methods like amniocentesis (Zhang *et al.*, 2020).

Gradually, the scope of ccfDNA research expanded to include cancer diagnostics. In this context, ccfDNA is utilized to identify tumor-specific mutations, offering a non-invasive alternative to tissue biopsies. This

application has proven particularly valuable in cancers where tissue biopsy is challenging or risky. Moreover, ccfDNA analysis allows for the monitoring of treatment response and the detection of minimal residual disease or emerging resistance to therapy, providing a dynamic view of the disease's progression and response to treatment ([Ignatiadis et al., 2021](#)).

Today, ccfDNA is being explored for its potential in various other conditions, including cardiovascular diseases, infectious diseases, and autoimmune disorders. This expansion signifies a paradigm shift in how diseases can be diagnosed and managed. The evolution of ccfDNA from a novel observation to a critical component in diagnostics underscores its growing importance in the broader context of molecular diagnostics and personalized medicine. It represents a convergence of technological innovation and clinical insight, paving the way for more precise, personalized, and non-invasive approaches to healthcare ([Huet and Salles, 2020](#)).

5. Molecular characteristics of ccfDNA

5.1. Composition and origins

The composition of circulating cell-free DNA (ccfDNA) is a reflection of its diverse origins. Predominantly, ccfDNA originates from apoptotic and necrotic cells, which release their DNA into the bloodstream during cell death. This process is a normal part of the body's physiological turnover and repair mechanisms. However, in the context of disease, particularly cancer, ccfDNA can also derive from tumor cells ([Mesquita et al., 2020](#)). This tumor-derived ccfDNA provides a unique window into the genetic makeup of the cancer, including mutations and genetic rearrangements characteristic of the tumor. Additionally, ccfDNA may originate from other sources such as the placenta in pregnant women, offering opportunities for non-invasive prenatal testing, or from inflamed tissues, which can be indicative of autoimmune diseases or infections. The heterogeneous nature of its sources makes ccfDNA a complex and rich source of information, encompassing both normal and pathological DNA signatures. This diversity in origin is key to the utility of ccfDNA in a wide range of diagnostic and therapeutic contexts, as it carries information about the health state of various tissues in the body ([Ju and Sun, 2022](#)).

5.2. Size distribution and fragmentation patterns

The size distribution of ccfDNA is a critical aspect of its molecular characterization. Typically, ccfDNA fragments are small, often ranging from 150 to 200 base pairs, corresponding to the size of DNA wrapped around a nucleosome. This size pattern suggests that ccfDNA fragmentation is a regulated process, likely associated with apoptosis, where enzymes systematically break down the DNA into these characteristic sizes ([Pataillot-Meakin et al., 2022](#)). However, variations in size distribution are observed in different pathological conditions, including cancer, where larger fragments might be present due to the mechanisms of cell death in tumors or the active release of DNA by cancer cells. These variations in size and fragmentation patterns are not just diagnostic markers; they also provide insights into the underlying biological processes of diseases. Understanding these fragmentation patterns is vital for improving the accuracy of ccfDNA-based diagnostics and for distinguishing between DNA from different origins ([Karaglani et al., 2022](#)). This knowledge can enhance the specificity of ccfDNA assays, allowing for more precise disease detection and monitoring ([Van Der Leest et al., 2022](#)).

5.3. Methylation patterns and genetic signatures

Methylation patterns and genetic signatures in ccfDNA provide a wealth of information for disease diagnosis and monitoring. DNA methylation, an epigenetic modification involving the addition of a methyl group to the DNA molecule, can reveal insights into gene regulation and disease states. In cancer, for example, tumor-derived ccfDNA often exhibits distinct methylation patterns that differ from those found in normal DNA ([Shrivastava et al., 2022](#)). These aberrant methylation patterns can be used to identify the presence and type of cancer, as they often correspond to specific oncogenic processes. Additionally, the analysis of genetic mutations, single nucleotide polymorphisms (SNPs), and other genomic alterations in ccfDNA has significant implications in personalized medicine. For instance, the identification of specific mutations in ccfDNA from a cancer patient can guide the selection of targeted therapies, tailored to the genetic makeup of the individual's tumor

(Poulet *et al.*, 2022). This level of precision is pivotal in the era of personalized medicine, enabling treatments that are more effective and have fewer side effects. The study of these molecular characteristics enhances the utility of ccfDNA as a non-invasive biomarker for various diseases, providing a window into the molecular underpinnings of an individual's health (Adachi *et al.*, 2022). The comprehensive understanding of the molecular characteristics of ccfDNA—its composition, size distribution, fragmentation patterns, and methylation profiles—offers invaluable insights into the physiology and pathology of diseases. This understanding is fundamental to the evolving use of ccfDNA in diagnostics, prognostics, and personalized medicine, enabling more precise and individualized approaches to healthcare.

6. Methodologies in ccfDNA analysis

6.1. Genomic sequencing techniques

The analysis of circulating cell-free DNA (ccfDNA) has been greatly advanced by genomic sequencing technologies, particularly by the advent of next-generation sequencing (NGS). NGS has revolutionized the field by enabling high-throughput, comprehensive analysis of ccfDNA, providing detailed insights into the genetic variations, mutations, and overall genomic landscape. This technique is highly sensitive and capable of detecting low-frequency genetic alterations, making it ideal for analyzing the often minute quantities of ccfDNA found in blood samples. Apart from NGS, PCR-based methods, such as quantitative PCR (qPCR) and digital PCR (dPCR), are employed for more targeted analysis. These methods are particularly useful when specific genetic markers or mutations are being investigated and are known for their high sensitivity and specificity (Szadkowska *et al.*, 2022). Additionally, advancements in sequencing technologies continue to improve the efficiency and reduce the costs of ccfDNA analysis, making it more accessible for routine clinical use (Wang *et al.*, 2022).

6.2. Bioinformatics tools and data analysis

The interpretation of the vast and complex data generated from ccfDNA sequencing relies heavily on bioinformatics tools. The role of bioinformatics in ccfDNA analysis cannot be overstated, as it encompasses the entire spectrum of data processing, from raw data management to advanced genomic analysis. These tools enable the detailed analysis of sequencing data to identify genetic mutations, epigenetic changes, and other genomic features of interest (Cheng *et al.*, 2022). One of the key challenges in bioinformatics is differentiating between ccfDNA originating from normal cells and that from pathological sources, such as tumor cells. This differentiation is crucial, especially in cancer diagnostics, where the detection of tumor-specific alterations in ccfDNA is vital. Sophisticated algorithms and data processing techniques are employed to filter out background noise and enhance the signal from relevant genomic alterations, translating raw sequencing data into meaningful clinical insights. This process is essential for accurate disease diagnosis, monitoring, and guiding therapeutic decisions (Renaud *et al.*, 2022).

6.3. Challenges and limitations in current methodologies

Despite the advancements in ccfDNA analysis, several challenges and limitations persist. One of the primary challenges is the low concentration of ccfDNA in blood, especially in the early stages of disease. This low abundance makes detection and analysis more difficult, requiring highly sensitive and precise techniques. Additionally, the high background of non-target DNA from normal cells can obscure the presence of disease-specific ccfDNA, impacting the sensitivity and specificity of the tests. This is particularly relevant in cancer diagnostics, where the differentiation between tumor-derived ccfDNA and normal ccfDNA is critical (Van Der Leest *et al.*, 2022). Another limitation is the variability in ccfDNA extraction and processing methods, which can lead to inconsistencies in results. Different extraction methods can yield ccfDNA of varying quality and quantity, which can affect downstream analysis. Addressing these challenges requires ongoing refinement of both sequencing technologies and bioinformatics approaches. This includes the development of more sensitive detection methods, improved data analysis algorithms, and standardized protocols for ccfDNA extraction and processing (Udomruk *et al.*, 2023). The goal is to achieve consistent, reliable, and reproducible results that can be confidently used in clinical decision-making. The future of ccfDNA analysis looks promising with continued technological advancements and a deeper understanding of the molecular complexities of ccfDNA.

As these challenges are addressed, the full potential of ccfDNA as a non-invasive diagnostic and monitoring tool can be realized, ushering in a new era of precision medicine.

7. ccfDNA in disease diagnosis

7.1. Early detection of diseases

The potential of circulating cell-free DNA (ccfDNA) in the early detection of diseases represents a groundbreaking shift in modern diagnostics. The presence and specific characteristics of ccfDNA in blood can serve as early indicators of a variety of diseases, far before traditional diagnostic methods can detect them. For instance, in the realm of cancer diagnostics, abnormal levels or specific mutations in ccfDNA can signal the onset of malignancies, often before any clinical symptoms are apparent ([Altieri et al., 2022](#)). This early detection capability of ccfDNA is not only significant for cancer but also extends to other conditions such as cardiovascular diseases and autoimmune disorders. The ability to detect these diseases early is crucial for initiating timely interventions, which can significantly improve patient outcomes. Early detection can lead to earlier treatment, potentially halting disease progression and reducing the burden on patients and healthcare systems ([Nidadavolu et al., 2022](#)).

7.2. ccfDNA in oncology: a focus on cancer detection

In oncology, ccfDNA has emerged as a cornerstone for cancer detection and monitoring. Tumor-derived ccfDNA, which carries genetic and epigenetic alterations reflective of the cancer cells, has proven to be a valuable biomarker for non-invasive cancer diagnostics. The analysis of ccfDNA can aid in identifying specific mutations that are critical in choosing targeted therapies, monitoring tumor burden to assess the effectiveness of treatment, and detecting minimal residual disease post-treatment. This aspect of cancer detection is particularly revolutionary as it allows for ongoing monitoring of the patient's cancer status, offering insights into tumor dynamics and the potential development of resistance to treatments ([Guemri et al., 2022](#)). The application of ccfDNA in cancer detection not only aids in early diagnosis but also plays a pivotal role in the customization of therapeutic strategies, based on the molecular profile of the tumor. This approach to cancer treatment, which is more personalized and responsive to the individual characteristics of each patient's cancer, signifies a major advancement in oncology ([Ramprakash et al., 2022](#)).

7.3. Applications in other diseases

Beyond oncology, the applications of ccfDNA are increasingly being recognized in a broad spectrum of other diseases. In prenatal testing, for example, ccfDNA derived from the placenta is used for non-invasive prenatal screening, offering a safer alternative to traditional methods for detecting chromosomal abnormalities in fetuses. In transplant medicine, ccfDNA can serve as a critical marker for organ rejection, detecting donor-derived DNA in the recipient's blood, which can signal the early stages of rejection before other symptoms appear. Additionally, there is growing interest in exploring the role of ccfDNA in inflammatory and autoimmune diseases, where it may help in understanding disease mechanisms and monitoring disease activity ([Cushen et al., 2022](#)). The use of ccfDNA in infectious diseases is also under investigation, where it could provide insights into pathogen load and treatment response. Moreover, ccfDNA is being studied for its potential in monitoring the efficacy of therapeutic interventions across these various conditions. These expanding applications of ccfDNA underscore its versatility and broad clinical utility in disease diagnosis and management, highlighting its potential as a transformative tool in modern medicine ([Kang et al., 2022](#)). The exploration of ccfDNA in disease diagnosis and management is an exciting and rapidly evolving area of research, offering promise for earlier detection, more accurate diagnostics, and more personalized treatment across a wide range of diseases.

8. ccfDNA in disease prognosis and therapeutic monitoring

8.1. Prognostic value in various diseases

The prognostic value of circulating cell-free DNA (ccfDNA) in various diseases is an area of growing interest and pivotal importance. In cancer, the quantity and specific characteristics of tumor-derived ccfDNA are

closely linked with disease aggressiveness and potential metastasis, offering a window into the overall prognosis of the patient. Elevated levels of ccfDNA, or specific changes in its genetic and epigenetic composition, are often associated with poor prognosis in several types of cancer. This relationship between ccfDNA characteristics and disease prognosis is not exclusive to oncology (Bradshaw *et al.*, 2022). In cardiovascular diseases, for instance, the presence and levels of ccfDNA can indicate the severity of tissue damage and help predict patient outcomes, such as the likelihood of recovery or the risk of future cardiac events. In autoimmune disorders and infectious diseases, the concentration and composition of ccfDNA can act as markers of disease activity and progression, aiding in the assessment of disease severity and the prediction of disease trajectory. This broad applicability across various diseases highlights the potential of ccfDNA as a universal biomarker in clinical prognostics (Saucedo-Sariñana *et al.*, 2022).

8.2. Monitoring treatment efficacy

ccfDNA is increasingly recognized as a valuable tool for monitoring treatment efficacy across various medical disciplines. In cancer treatment, dynamic changes in the levels and genetic composition of ccfDNA can provide real-time feedback on the tumor's response to therapy. This enables clinicians to assess the effectiveness of treatment regimens in real-time and make timely adjustments to the therapeutic approach. This application is particularly valuable in the realm of personalized medicine, where treatments are increasingly being tailored to the genetic profile of the individual's disease (Chedid *et al.*, 2022). The monitoring of ccfDNA allows for a more responsive approach to treatment, enabling the optimization of therapeutic strategies based on the molecular response detected. Beyond oncology, in contexts such as organ transplantation or chronic diseases, monitoring ccfDNA can offer insights into the effectiveness of interventions, guiding clinical decision-making, and enhancing patient care (Prakash *et al.*, 2023).

8.3. Predicting disease relapse

Another crucial application of ccfDNA lies in its ability to predict disease relapse. In oncology, the detection of specific genetic mutations or an increase in ccfDNA levels post-treatment can serve as early warning signs of minimal residual disease or an impending relapse. This capability of early detection allows for timely and potentially life-saving interventions, improving patient outcomes and offering a proactive approach to disease management. The predictive power of ccfDNA extends beyond cancer, holding promise in various other diseases where the monitoring of ccfDNA can aid in predicting disease flare-ups or relapse. This can be particularly valuable in managing chronic conditions, allowing for preemptive adjustments in treatment to mitigate the impact of a relapse or exacerbation (Shields *et al.*, 2022).

The utilization of ccfDNA in disease prognosis and therapeutic monitoring represents a significant advance in modern medicine. Its non-invasive nature, combined with the dynamic and sensitive reflection of disease states, positions ccfDNA as an invaluable tool in disease management, providing clinicians with critical insights that can guide therapeutic decisions and improve patient outcomes (Paschold and Binder, 2022).

9. Dynamics of ccfDNA: release and clearance

9.1. Mechanisms of ccfDNA release into the bloodstream

Understanding the mechanisms behind the release of circulating cell-free DNA (ccfDNA) into the bloodstream is crucial for interpreting its diagnostic and prognostic significance. The primary pathways of ccfDNA release are apoptosis (programmed cell death) and necrosis (cell death due to injury or disease), each characterized by distinct patterns of DNA fragmentation. In apoptosis, DNA is systematically fragmented into distinct sizes, typically around 180-200 base pairs, correlating with nucleosome units, a pattern indicative of an orderly cellular disassembly process (Solanky *et al.*, 2022). Conversely, necrosis results in the release of larger and more random DNA fragments due to the chaotic and uncontrolled breakdown of cells. In the context of cancer, another noteworthy mechanism is the active secretion of DNA by tumor cells, contributing to the pool of ccfDNA in the bloodstream. This tumor-derived ccfDNA can carry specific genetic mutations and alterations characteristic of the cancer, providing valuable insights into its molecular nature. The diverse origins and mechanisms of release of ccfDNA influence its composition and concentration, reflecting the physiological or pathological state of the body, thus offering key insights into various diseases (Colmenares *et al.*, 2022).

9.2. Clearance processes and diagnostic implications

The clearance of ccfDNA from the bloodstream is a critical aspect that significantly affects its diagnostic utility. ccfDNA is predominantly cleared through the liver and kidneys, processes which contribute to its relatively short half-life in the circulation. This rapid turnover implies that ccfDNA levels can provide real-time information about the current state of cell death, disease progression, or response to therapy. The dynamics of ccfDNA clearance are therefore essential in interpreting its levels, as alterations in clearance rates can significantly affect the accumulation and overall concentration of ccfDNA in the bloodstream. Factors such as liver or kidney dysfunction can impact these rates, leading to elevated levels of ccfDNA that might be misinterpreted as disease indicators (Schroers-Martin *et al.*, 2022). Additionally, certain therapeutic interventions and medications can also influence ccfDNA clearance, underscoring the need for careful consideration of these factors when using ccfDNA as a diagnostic or monitoring tool. Understanding these clearance mechanisms and their potential impact is vital for accurate diagnosis and prognosis, as fluctuations in ccfDNA levels can be reflective of changes in disease status, therapeutic efficacy, or even organ function (Csoma *et al.*, 2022). The dynamics of ccfDNA release and clearance play a pivotal role in its utility as a biomarker, influencing both its diagnostic and prognostic applications. These processes are critical in determining not only the presence and quantity of ccfDNA in the bloodstream but also in providing valuable information about the nature and stage of the underlying disease or condition. The ongoing study of these dynamics is key to enhancing the clinical utility of ccfDNA, furthering its role in non-invasive diagnostics, disease monitoring, and personalized medicine.

10. ccfDNA in personalized medicine

10.1. Customizing therapeutic strategies

The integration of circulating cell-free DNA (ccfDNA) analysis into personalized medicine is revolutionizing the approach to customizing therapeutic strategies. ccfDNA provides a unique molecular snapshot of a patient's disease through non-invasive means, enabling the tailoring of treatment plans to the individual's specific disease profile. In the field of oncology, this means being able to identify targetable mutations and resistance mechanisms in cancer patients, thereby guiding the selection of targeted therapies (Jelski and Mroczko, 2022). This approach moves away from the 'one-size-fits-all' treatment model, allowing for a more focused and effective strategy that can significantly reduce the trial-and-error aspect of cancer treatment. Beyond oncology, the implications of ccfDNA in personalizing treatment strategies are vast. For instance, in cardiovascular diseases, ccfDNA profiling can help in predicting and managing patient response to certain drugs, potentially reducing side effects and improving treatment efficacy (Tamm *et al.*, 2022). This customization is central to the ethos of personalized medicine, enhancing patient outcomes and optimizing the quality of life by providing more precise, tailored healthcare solutions.

10.2. Liquid biopsies: advantages and prospects

Liquid biopsies, primarily involving the analysis of ccfDNA from blood samples, have several distinct advantages over traditional tissue biopsies. Their minimally invasive nature greatly reduces patient discomfort and the risk associated with conventional biopsy procedures. Liquid biopsies are particularly beneficial in providing real-time disease monitoring. In cancer, for example, they enable the tracking of tumor evolution and the detection of emerging resistance to therapies, offering critical insights that can guide treatment adjustments. This real-time monitoring is also invaluable in early detection of disease recurrence, often before it becomes clinically apparent (Hsu *et al.*, 2022). The utility of liquid biopsies is expanding beyond oncology into other medical fields such as cardiovascular, neurological, and infectious diseases, offering a broader scope for disease management and monitoring. The potential of liquid biopsies in clinical practice is substantial, signaling a shift towards more dynamic, responsive, and patient-centered healthcare (Van't Erve *et al.*, 2022).

10.3. Ethical and practical considerations

The use of ccfDNA in personalized medicine also entails significant ethical and practical considerations. Privacy and data security are of utmost importance, given the highly personal and sensitive nature of genetic information derived from ccfDNA. Ensuring informed consent and ethical handling of this genetic data is

critical in maintaining patient trust and upholding ethical standards in healthcare. Additionally, the interpretation of ccfDNA results demands a high level of expertise in genomics and bioinformatics, underscoring the need for adequately trained professionals in clinical settings. This requirement highlights a growing need for investment in education and training in these areas to support the expanding use of ccfDNA. Furthermore, the cost and accessibility of ccfDNA-based tests are critical factors to consider. It is essential that these innovative diagnostic tools are made accessible and affordable to a wide range of patient populations to ensure equitable healthcare benefits (Glyn and Purcell, 2022).

The role of ccfDNA in personalized medicine is at the forefront of a rapidly evolving landscape, offering promising prospects for individualized treatment and enhanced patient care. However, this advancement must be navigated with careful consideration of the associated ethical, practical, and accessibility challenges (Abramson *et al.*, 2023).

11. Future directions and research needs

11.1. Emerging technologies and innovations

The field of circulating cell-free DNA (ccfDNA) stands on the cusp of significant advancements driven by emerging technologies and innovations. Future research is expected to majorly focus on enhancing the sensitivity and specificity of ccfDNA detection. This advancement is particularly crucial for early-stage disease detection where ccfDNA levels are often very low. The development of more sophisticated sequencing technologies, coupled with advanced bioinformatics tools, is likely to play a pivotal role in this regard. Innovations in nanotechnology and microfluidics are anticipated to facilitate more efficient isolation and analysis of ccfDNA, potentially allowing for the capture of even the smallest fragments with high precision. Additionally, the integration of artificial intelligence and machine learning in data analysis could revolutionize the interpretation of ccfDNA data, enabling more accurate and predictive analyses. These advancements are not just incremental improvements but are expected to open new frontiers in diagnostics and therapeutics, enhancing the scope and accuracy of ccfDNA applications (Cheng *et al.*, 2022).

11.2. Standardizing protocols for clinical utility

A critical area of focus for the future is the standardization of protocols for ccfDNA analysis to ensure its clinical utility. Currently, variations in sample collection, DNA extraction, sequencing, and data analysis methods can lead to inconsistencies in results. Establishing uniform, validated protocols is essential for producing reliable and reproducible results, which is paramount for clinical decision-making. This effort would involve the development of standardized procedures for each step of the ccfDNA analysis process, as well as establishing quality control measures and reference standards. Such standardization efforts are crucial for the integration of ccfDNA analysis into routine clinical practice, ensuring that the benefits of this technology can be universally accessed and applied across different healthcare settings (Sivapalan *et al.*, 2023).

11.3. Expanding the horizons: beyond oncology

While the application of ccfDNA in oncology is well-established, its potential utility extends far beyond cancer diagnosis and management. Future research is poised to explore the role of ccfDNA in a broader range of diseases. This includes its application in cardiovascular diseases for detecting early signs of heart damage, in neurodegenerative diseases for tracking disease progression, and in autoimmune diseases for monitoring flare-ups. Additionally, the role of ccfDNA in infectious diseases, prenatal testing, and transplant medicine presents vast areas for exploration. These expanded applications of ccfDNA have the potential to significantly enhance our understanding of various diseases and open up new avenues for diagnosis, prognosis, and personalized treatment strategies. This broadening of scope signifies a shift towards a more holistic application of ccfDNA in medicine, transcending traditional boundaries and offering a more comprehensive approach to healthcare (Ye *et al.*, 2022).

The future of ccfDNA research is vibrant and holds immense promise for transforming diagnostic and therapeutic approaches in medicine. As we move forward, ccfDNA is set to become a cornerstone in the evolution towards more personalized, precise, and effective healthcare solutions.

12. Conclusion

12.1. Summary of key findings

This comprehensive review of circulating cell-free DNA (ccfDNA) underscores its significant potential in revolutionizing the landscape of disease diagnosis and treatment. Key findings include the characterization of ccfDNA's molecular composition, origins, and the mechanisms of its release and clearance. Notably, the analysis of ccfDNA has emerged as a critical tool in early disease detection, particularly in oncology, where it is used for cancer diagnosis and monitoring. This is a significant stride forward, as it allows for the early identification of cancers, potentially when they are most treatable. The prognostic value of ccfDNA across various diseases is another key finding, highlighting its role in predicting disease progression and treatment outcomes. ccfDNA's ability to monitor treatment efficacy and predict disease relapse further amplifies its significance in personalized medicine. Advancements in genomic sequencing techniques and bioinformatics tools have greatly enhanced our ability to analyze ccfDNA, though challenges in current methodologies still need addressing. The integration of ccfDNA into personalized medicine, particularly through its application in liquid biopsies, represents a significant shift towards more tailored and patient-centric healthcare, reflecting a deeper understanding of individual disease processes and responses to treatment.

12.2. Potential impact and future perspectives

The potential impact of ccfDNA is vast, stretching across various domains of healthcare. As a non-invasive biomarker, ccfDNA offers a unique window into the molecular nature of diseases, facilitating early detection, and allowing for the development of personalized treatment strategies. Looking ahead, the future of ccfDNA research is brimming with potential, anticipated to be marked by further technological advancements, more rigorous standardization of protocols, and an expansion into diverse medical fields beyond oncology. These developments promise to refine the precision and efficacy of medical interventions, ultimately enhancing patient outcomes and the quality of life. The expanding research and clinical application of ccfDNA are paving the way for innovative diagnostic and therapeutic approaches, marking a new era in molecular diagnostics and personalized medicine. This evolution points towards a future where healthcare is more proactive, predictive, and personalized, significantly impacting the management and treatment of a wide array of diseases.

The journey of ccfDNA from a novel scientific discovery to a cornerstone in modern medicine exemplifies the dynamic nature of medical research and its profound impact on patient care. As we continue to explore and understand the full potential of ccfDNA, it holds the promise of transforming healthcare, offering more effective, efficient, and personalized medical solutions.

Acknowledgment

I would like to express our heartfelt appreciation and gratitude to Prince Sattam bin Abdulaziz University for their unwavering support and encouragement throughout our research project. Without their support, this study would not have been possible. I would also like to extend our sincere thanks to the faculty members and research staff at Prince Sattam bin Abdulaziz University, namely Prof. Farag Ellessawy, Dr. Mohammad Mahzari, Dr. Mohammad Shaie Al-Matrafi and Dr. Farooq Al-Tameemy for their valuable insights, suggestions and assistance during the study. Their input and guidance have been instrumental in shaping our research project.

Conflict of interest

There is no conflict of interest associated with this work.

References

- Abramson, D.H., Mandelker, D., Brannon, A.R., Dunkel, I., Benayed, R., Berger, M.F., Arcila, M.E., Ladanyi, M., Friedman, D.N., Jayakumaran, G., Diosdado, M.S., Robbins, M., Haggag-Lindgren, D., Shukla, N., Walsh, M.F., Kothari, P., Tsui, D. and Francis, J.H. (2023). [Mutant-RB1 circulating tumor DNA in the blood of unilateral retinoblastoma patients: what happens during enucleation surgery: a pilot study. PLOS ONE, 18. doi: 10.1371/journal.pone.0271505.](https://doi.org/10.1371/journal.pone.0271505)

- Adachi, J., Mishima, K. and Nishikawa, R. (2022). BIOM-30: analysis of glioma-related genes using a breakthrough amplification technique for cell-free dna in cerebrospinal fluid. *Neuro-oncol.* doi: 10.1093/neuonc/noac209.040.
- Altieri, B., Appenzeller, S., Arlt, W. *et al.* (2022). OR04-5 circulating cell-free DNA-based biomarkers for prognostication and disease surveillance in adrenocortical carcinoma. *J. endocr. soc.*, 6: A81-A82. doi: 10.1210/jendso/bvac150.169.
- Ashley, C., Selenica, P., Patel, J., Wu, M., Nincevic, J., Lakhman, Y. and Jewell, E. (2022). High-sensitivity mutation analysis of cell-free DNA for disease monitoring in endometrial cancer. *Clin. cancer res.* doi: 10.1158/1078-0432.CCR-21-3612.
- Bradshaw, J., Cushen, S., Phillips, N. and Gouloupoulou, S. (2022). Circulating cell-free mitochondrial DNA in pregnancy. *Physiology.* doi: 10.1152/physiol.00037.2021.
- Carrasco, R., Ingelmo Torres, M., Gómez, A., Trullas, R., Roldán, F., Ajami, T. and Mengual, L. (2022). Cell-free DNA as a prognostic biomarker for monitoring muscle-invasive bladder cancer. *Int. j. mol. sci.*, 23. doi: 10.3390/ijms23073650.
- Chedid, J., Allam, S., Chamseddine, N., Bou Zerdan, M., El Nakib, C. and Assi, H. (2022). Role of circulating tumor DNA and circulating tumor cells in breast cancer: History and updates. *SAGE open med.*, 10. doi: 10.1177/20503121221077838.
- Cheng, A., Widman, A.J., Arora, A. *et al.* (2022). Whole genome error-corrected sequencing for sensitive circulating tumor DNA cancer monitoring. *bioRxiv.* doi: 10.1101/2022.11.17.516904.
- Cheng, A.P., Cheng, M., Loy, C.J., Lenz, J.L., Chen, K., Smalling, S., Burnham, P., Timblin, K., Orejas, J., Silverman, E.A., Polak, P., Marty, F., Ritz, J. and De Vlaminc, I. (2022). Cell-free DNA profiling informs all major complications of hematopoietic cell transplantation. *Proc. natl. acad. sci. USA.*, 119. doi: 10.1073/pnas.2113476118.
- Colmenares, R., Alvarez, N., Barrio, S., Martínez-López, J. and Ayala, R. (2022). The minimal residual disease using liquid biopsies in hematological malignancies. *Cancers.*, 14. doi: 10.3390/cancers14051310.
- Csoma, S.L., Bedekovics, J., Veres, G., Ároksszállási, A., András, C., Méhes, G. and Mokánszki, A. (2022). Circulating cell-free DNA-based comprehensive molecular analysis of biliary tract cancers using next-generation sequencing. *Cancers.*, 14. doi: 10.3390/cancers14010233.
- Cushen, S., Ricci, C.A., Bradshaw, J. *et al.* (2022). Reduced maternal circulating cell free mitochondrial DNA is associated with the development of preeclampsia. *J. am. heart. Assoc.*, 11. doi: 10.1161/JAHA.121.021726.
- Gianni, C., Palleschi, M., Merloni, F., Blevé, S., Casadei, C., Sirico, M. and de Giorgi, U. (2022). Potential impact of preoperative circulating biomarkers on individual escalating/de-escalating strategies in early breast cancer. *Cancers.*, 15. doi: 10.3390/cancers15061356.
- Glyn, T. and Purcell, R. (2022). Circulating bacterial DNA: a new paradigm for cancer diagnostics. *Front med.*, 9. doi: 10.3389/fmed.2022.831096.
- Guemri, J., Pierre-Jean, M., Brohard, S. *et al.* (2022). Methylated ccfDNA from plasma biomarkers of Alzheimer's disease using targeted bisulfite sequencing. *Epigenomics.* doi: 10.2217/epi-2021-0491.
- Hosseinalizadeh, H., Mahmoodpour, M. and Ebrahimi, A. (2021). The role of cell-free circulating DNA in the diagnosis and prognosis of breast cancer. *Ann. cancer res. Ther.* doi: 10.4999/acr.2021.001.
- Hsu, P.-S., Chen, D., Chien, H.-P., Yeh, C., Hong, P., Lin, S., Lee, J. and Lai, H. (2022). Detection of molecular residual disease (MRD) for cancer management: lessons from longitudinal profiling of NSCLC patients undergoing chemotherapy or targeted therapy. *J. clin. oncol.* doi: 10.1200/jco.2022.40.16_suppl.e15020.
- Huet, S. and Salles, G. (2020). Potential of circulating tumor DNA for the management of patients with lymphoma. *JCO oncol. pract.* doi: 10.1200/OP.20.00103.
- Ignatiadis, M., Sledge, G. and Jeffrey, S. (2021). Liquid biopsy enters the clinic — implementation issues and future challenges. *Nat. rev. clin. oncol.*, 18: 297-312. doi: 10.1038/s41571-020-00458-8.

- Jelski, W. and Mroczko, B. (2022). Molecular and circulating biomarkers of gastric cancer. *Int. j. mol. sci.*, 23. doi: 10.3390/ijms23147588.
- Ju, J. and Sun, K. (2022). Plasma cell free DNA analysis for COVID 19 and beyond. *Clin. transl. discov.*, 2. doi: 10.1002/ctd2.71.
- Kang, J.-K., Kim, H.-P., Lim, Y. *et al.* (2022). Abstract 5164: cell-free DNA (cfDNA) fragment size as a potential quantitative biomarker for metastatic colorectal cancer (mCRC). *Cancer res.* doi: 10.1158/1538-7445.am2022-5164.
- Karaglani, M., Panagopoulou, M., Cheimonidi, C. *et al.* (2022). Liquid biopsy in type 2 diabetes mellitus management: building specific biosignatures via machine learning. *J. clin. med.*, 11. doi: 10.3390/jcm11041045.
- Mesquita, A., Costa, J.L. and Schmitt, F. (2020). Utility of circulating tumor DNA in different clinical scenarios of breast cancer. *Cancers.*, 12. doi: 10.3390/cancers12082068.
- Nidadavolu, L.S., Feger, D., Wu, Y. *et al.* (2022). Circulating cell-free genomic DNA is associated with an increased risk of dementia and with change in cognitive and physical function. *J. alzheimers dis.* doi: 10.3233/jad-220301.
- Paschold, L. and Binder, M. (2022). Circulating tumor DNA in gastric and gastroesophageal junction cancer. *Curr. oncol.*, 29: 1430-1441. doi: 10.3390/curroncol29030120.
- Pataillot-Meakin, T., Ladame, S. and Bevan, C.L. (2022). Technologies for size-based analysis of circulating cell-free DNA: limitations and clinical implementation. *Crit. rev. oncog.*, 27(1): 97-108. doi: 10.1615/critrevoncog.2022043215.
- Peng, Y., Mei, W., Ma, K. and Zeng, C. (2021). Circulating tumor DNA and minimal residual disease (MRD) in solid tumors: current horizons and future perspectives. *Front oncol.*, 11. doi: 10.3389/fonc.2021.699851.
- Poulet, G., Hulot, J., Blanchard, A. *et al.* (2022). Circadian rhythm and circulating cell-free DNA release on healthy subjects. doi: 10.21203/rs.3.rs-1270021/v1.
- Prakash, V., Gao, L. and Park, S.-J. (2023). Evolving applications of circulating tumor DNA in merkel cell carcinoma. *Cancers.*, 15. doi: 10.3390/cancers15030609.
- Ramprakash, J., Butler, M.G., Garlick, R.K. and Konigshofer, Y. (2022). Abstract 3376: novel reference materials for the analysis of methylation in liquid biopsies. *Cancer res.* doi: 10.1158/1538-7445.am2022-3376.
- Renaud, G., Nørgaard, M., Lindberg, J. *et al.* (2022). Unsupervised detection of fragment length signatures of circulating tumor DNA using non-negative matrix factorization. *eLife.*, 11. doi: 10.7554/eLife.71569.
- Saucedo-Sariñana, A.M., Lugo-Escalante, C.R., Barros-Núñez, P. *et al.* (2022). Circulating cell-free-DNA concentration is a good biomarker for diagnosis of colorectal cancer in Mexican patients. *Cell mol. biol.*, 68(6): 1-8. doi: 10.14715/cmb/2022.68.6.1.
- Schroers-Martin, J., Alig, S., Garofalo, A., Tessoulin, B., Sugio, T. and Alizadeh, A. (2022). Molecular monitoring of lymphomas. *Annu. rev. pathol. mech. dis.* doi: 10.1146/annurev-pathol-050520-044652.
- Sener, U., Kumthekar, P. and Boire, A. (2021). Advances in the diagnosis, evaluation, and management of leptomeningeal disease. *Neuro-oncology advances.*, 3(v86-v95). doi: 10.1093/noajnl/vdab086.
- Shields, M., Chen, K., Dutcher, G., Patel, I. and Pellini, B. (2022). Making the rounds: exploring the role of circulating tumor DNA (ctDNA) in non-small cell lung cancer. *Int. j. mol. sci.*, 23. doi: 10.3390/ijms23169006.
- Shrivastava, A., Singh, G., Tiwari, K. *et al.* (2022). A study for evaluating clinical relevance of circulating cell-free DNA in cervical cancer. *J. cancer res. ther.*, 18: 1553-1558. doi: 10.4103/jcrt.jcrt_415_20.
- Sivapalan, L., Murray, J., Canzoniero, J.V., Landon, B.V., Jackson, J., Scott, S.L., Lam, V., Levy, B., Sausen, M. and Anagnostou, V. (2023). Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. *J. immunother. cancer.*, 11. doi: 10.1136/jitc-2022-005924.
- Solanky, D., Ahmed, A.A., Fierer, J., Golts, E., Jones, M.R. and Mehta, S. (2022). Utility of plasma microbial cell-free DNA decay kinetics after aortic valve replacement for bartonella endocarditis: case report. *Front infect dis.*, 3. doi: 10.3389/fitd.2022.842100.

- Szadkowska, P., Roura, A.J., Wojtace, B. *et al.* (2022). Improvements in quality control and library preparation for targeted sequencing allowed detection of potentially pathogenic alterations in circulating cell-free DNA derived from plasma of brain tumor patients. *Cancers.*, 14. doi: 10.3390/cancers14163902.
- Tamm, M., Kals, M., Annilo, T., Oselin, K., Keerma, K., Kivistik, P.A., Nurm, M., Saare, M., Jaal, J. and Tõnisson, N. (2022). Prognostic utility of targeted circulating cell-free DNA versus formalin-fixed paraffin-embedded DNA mutation analysis for advanced lung cancer. *Int j. oncol. res.* doi: 10.23937/2643-4563/1710033.
- Telekes, A. and Horváth, A. (2022). The role of cell-free DNA in cancer treatment decision making. *Cancers.*, 14. doi: 10.3390/cancers14061535.
- Thakral, D., Das, N., Basnal, A. and Gupta, R. (2020). Cell-free DNA for genomic profiling and minimal residual disease monitoring in Myeloma- are we there yet? *Am. j. blood res.*, 10(3): 26-45. doi: 10.14218/AJBR.2020.00016.
- Tripathi, V.P., Aneebuddin, M.K., Alex, C. and Moharir, K. (2022). Evaluating clinical applications of liquid biopsy by combining circulating tumor DNA and tumor cells. *Curr. res. pharm. sci.* doi: 10.1016/j.crphar.2022.100044.
- Udomruk, S., Phanphaisarn, A., Kanthawang, T. *et al.* (2023). Characterization of cell-free DNA size distribution in osteosarcoma patients. *Clin. cancer res.* doi: 10.1158/1078-0432.CCR-22-2912.
- Van't Erve, I., Medina, J., Leal, A., Papp, E., Phallen, J., Adleff, V., Chiao, E., Arun, A.S., Bolhuis, K., Simmons, J., Karandikar, A., Valkenburg, K.C., Sausen, M., Angiuoli, S.V., Scharpf, R., Punt, C., Meijer, G., Velculescu, V. and Fijneman, R. (2022). Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells. *Clin. cancer res.*, 29: 899-909. doi: 10.1158/1078-0432.ccr-22-2538.
- Van Der Leest, P., Janning, M., Rifaela, N. *et al.* (2022). Abstract 3411: detection and monitoring of tumor-derived mutations in ctDNA using the UltraSEEK lung panel on the MassARRAY system in metastatic NSCLC patients. *Cancer res.* doi: 10.1158/1538-7445.am2022-3411.
- Van Der Leest, P., Ketelaar, E.M., Van Noesel, C.V. *et al.* (2022). Dutch national round robin trial on plasma-derived circulating cell-free DNA extraction methods routinely used in clinical pathology for molecular tumor profiling. *Clin. chem.* doi: 10.1093/clinchem/hvac069.
- van Zogchel, L.V., van Wezel, E.M., van Wijk, J., Stutterheim, J., Bruins, W., Zappeij-Kannegieter, L. and Tytgat, G.A. (2020). Hypermethylated RASSF1A as circulating tumor DNA marker for disease monitoring in neuroblastoma. *JCO precis. oncol.*, 4. doi: 10.1200/PO.19.00331.
- Wang, W., Gao, T., Luo, J. *et al.* (2022). Size distribution analysis of residual host cell DNA fragments in lentivirus by CGE LIF. *Electrophoresis.*, 44: 462-471. doi: 10.1002/elps.202200218.
- Ye, X., Li, W., Zhang, L.-F. and Yu, J. (2022). Clinical significance of circulating cell-free DNA detection in multiple myeloma: a meta-analysis. *Front oncol.*, 12. doi: 10.3389/fonc.2022.852573.
- Zhang, S.V., Tan, M., Navarro, F.C., Northcott, J.M., Ma, S., Nelson, C. and Chen, R.O. (2020). Profiling tumor circulating cell-free DNA with an enhanced whole-exome to enable sensitive assessment of somatic mutations. *J. immuno. ther. cancer.*, 8. doi: 10.1136/jitc-2020-001853.
- Zhang, S.V., Tan, M., Northcott, J.M., Ma, S., Nelson, C.S., Bentley, L. and Chen, R.O. (2020). Abstract 1989: enhanced whole exome profiling of tumor circulating cell-free DNA enables sensitive assessment of tumor mutations. *Clin. trials.*, 80(1989-1989). doi: 10.1158/1538-7445.am2020-1989.